Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
T-cell lymphoblastic lymphomas are highly aggressive non-Hodgkin's lymphoma (NHL) and account for approximately 3% of all adult NHL histologies, with poor prognosis. We describe a 38-year-old patient with T-cell lymphoblastic lymphoma, who responds to bortezomib and doxorubincin combination, following a failure of conventional chemotherapy. Two months after treatment, the patient showed near complete remission of the lymphadenopathy. These data suggest a possible synergistic effect with bortezomib in combination with doxorubincin and dexamethasone. To our knowledge, this is the first case of T-cell lymphoblastic lymphoma treated with bortezomib.
Mai
Wenyuan
W
Department of Hematology, the First Affiliated Hospital of ZheJiang University, HangZhou, ZheJiang, China. wymai65@yahoo.com.cn
Meng
Haitao
H
Jin
Jie
J
Wang
Lei
L
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004357:Drug Synergism; D006801:Humans; D016399:Lymphoma, T-Cell / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011719:Pyrazines / Q000008:administration & dosage*; D011859:Radiography; D012074:Remission Induction
D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D004317:Doxorubicin